3-Year trial tests if hair loss drug keeps working for kids
NCT ID NCT07029828
Summary
This study aims to learn about the long-term safety and effectiveness of the medicine ritlecitinib for treating severe alopecia areata, a condition that causes significant hair loss. It is for children and teenagers who have already finished one of two previous Pfizer studies for this condition. All participants will take the study medicine daily for up to three years to see if it continues to help regrow hair and is safe over a long period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE ALOPECIA AREATA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dawes Fretzin Clinical Research Group, LLC
RECRUITINGIndianapolis, Indiana, 46250, United States
-
Northwest Dermatology Institute
RECRUITINGPortland, Oregon, 97210, United States
-
Pediatric Skin Research
RECRUITINGMiami, Florida, 33156, United States
-
Texas Dermatology and Laser Specialists
RECRUITINGSan Antonio, Texas, 78218, United States
Conditions
Explore the condition pages connected to this study.